Lamzede (velmanase alfa) Medical Benefit Medication Utilization Policy
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical benefit coverage criteria, authorization, and coding guidance for velmanase alfa (Lamzede) for treatment of alpha-mannosidosis; applies to providers requesting prior authorization from the payer for affected members.
No material clinical or coverage changes in this revision.
Coverage criteria for Lamzede (velmanase alfa)
inv-01: Initial Therapy
Covered when ALL of the following are met
inv-02: Continuation Therapy
Covered when ALL of the following are met
Approval period: up to 1 year
Coverage for velmanase alfa (Lamzede) for treatment of alpha-mannosidosis is provided when all specified criteria are met. For initial therapy, the member must have: (1) a documented diagnosis of alpha-mannosidosis; (2) diagnostic confirmation with an enzyme assay showing alpha-mannosidase activity < 10% of normal; and (3) the medication prescribed by, or in consultation with, a specialist experienced in management of lysosomal storage disorders. Prior authorization is required and, if approved, coverage is granted for up to 1 year.
For continuation therapy, coverage is allowed when all continuation criteria are met: (1) diagnosis of alpha-mannosidosis is documented; and (2) the member is being actively monitored, has demonstrated benefit from velmanase alfa, and is considered appropriate to continue therapy. Continuation authorizations are also issued for up to 1 year when these conditions are satisfied.
Billing and coding
| J0217 |
What providers must do / watch for
Prior authorization required with diagnostic confirmation and specialist involvement
Prior authorization is required for velmanase alfa (Lamzede). Submit documentation of diagnostic confirmation — an enzyme assay demonstrating alpha-mannosidase activity < 10% of normal — and evidence that the drug was prescribed by, or in consultation with, a specialist familiar with lysosomal storage disorders. Approvals, when granted, are for up to 1 year.
- Applicable HCPCS code: J0217
Confirm specialist involvement and enzyme assay before submission
Ensure the request includes specialist involvement (prescribed by or in consultation with a specialist familiar with lysosomal storage disorders) and the required enzyme assay result; missing either may lead to denial.
- Prescriber is a specialist or consultation documentation is provided
- Enzyme assay result showing alpha-mannosidase activity < 10% of normal
Required documentation for prior authorization
Documentation submitted with the authorization request must include a diagnosis of alpha-mannosidosis and the enzyme assay demonstrating alpha-mannosidase activity < 10% of normal; note whether the medication was prescribed by, or in consultation with, a specialist experienced in lysosomal storage disorders.
- Diagnosis of alpha-mannosidosis
- Enzyme assay result documenting alpha-mannosidase activity < 10% of normal
- Record of specialist prescribing or consultation
Denial triggers: missing diagnostic proof or specialist involvement
Requests missing the required diagnostic documentation (enzyme assay showing alpha-mannosidase activity < 10% of normal) or lacking specialist involvement (no evidence that a specialist prescribed or was consulted) may be denied.
- Absence of enzyme assay result demonstrating < 10% activity
- No documentation of specialist prescribing or consultation
Background and clinical context
Alpha-mannosidosis is a rare lysosomal storage disorder treated with enzyme replacement therapy such as velmanase alfa (Lamzede). Diagnosis is confirmed by measurement of alpha-mannosidase enzyme activity; the policy requires an enzyme assay demonstrating alpha-mannosidase activity < 10% of normal for diagnostic confirmation. Management and prescribing should involve a specialist familiar with lysosomal storage disorders to ensure appropriate evaluation and monitoring.
Definitions and thresholds
Initial therapy criteria for velmanase alfa
inv-13: Initial Therapy
Initial coverage criteria for velmanase alfa
Continuation therapy criteria for velmanase alfa
inv-14: Continuation Therapy
Continuation of velmanase alfa for alpha-mannosidosis
Quantity limits and administration
Site of care considerations
No specific site‑of‑care restriction listed
No site‑of‑care restriction specified in the policy; providers should follow usual billing and placement practices for therapeutic infusions or administrations of velmanase alfa.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.